Feat: The Biosimilars Era; Challenges in pharma comms; This year's top clinical researchers
Biosimilars may have proven their worth, but how can adoption be sped up?
Pharma comms is one of the most dynamic sectors of the industry. So, what should be on communicators’ radar?
Can pharma prove that being patient centric is more than just a fad?
Celebrating 25 years of the Marketer of the Year competition
The PharmaTimes International Clinical Researcher of the Year Awards Ceremony & Gala Dinner is to take place next Thursday (17 May) at the Millenium Gloucester Hotel in London's Kensington.
The European Commission has green-lighted Novartis unit Sandoz’ Zessly, a biosimilar version of Johnson & Johnson and Merck & Co’s Remicade
24th May 2018
The Care Quality Commission has published a report concluding that some patients visiting A&E departments over the winter period received care that was "wholly unsatisfactory".
24th May 2018
It is currently looking unlikely that Chiesi’s Lamzede will become routinely available on the NHS for patients with alpha-mannosidosis, after cost-regulators issued a preliminary rejection of the drug.
24th May 2018
Tax rises will likely be needed to keep the quality of health and social care as it is now while the system contends with the growing demands of an ageing demographic, concludes a report by The Institute for Fiscal Studies and the Health Foundation.
24th May 2018
US regulators have approved a new indication for Amgen’s Prolia, allowing its use to treat glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture.
23rd May 2018
Chris Molloy and James Peach from the Medicine Discovery Catapult talk about humanising discovery and real world evidence and improving access for SMEs to the NHS Ecosystem
How do life sciences firms measure the efficiency of regulatory submissions management, and what’s the key to improving productivity?
The steps pharma organisations can take towards GDPR readiness and why the new regulation could be a positive catalyst for change
What advances in drug delivery devices are in store for us over the next 20-30 years?
Dr Karishma Patel talks to PharmaTimes about the challenges of life with this ultra-rare genetic disorder
Pharma comms is one of the most dynamic sectors of the industry. So, what should be on communicators’ radar?
Biosimilars may have proven their worth, but how can adoption be sped up?
CEO Christian Wandersee explains the hurdles and hopes when developing drugs for traumatic brain injury, a devastating condition for which there is no existing drug treatment
We caught up with IQVIA’s SVP global technology solutions, Tal Rosenberg, at the 2018 eyeforpharma Barcelona conference as the company announced the EU launch of its Orchestrated Customer Engagement product, which aims to harmonise pharma's interaction with customers
Gene therapy still needs to overcome some major hurdles to truly fulfil its promise
Ana Nicholls asks whether GSK’s revenue drop is a short-term blip or a sign of bigger problems
Medical conferences provide one of the most valuable opportunities for pharma to engage with key stakeholders, but until recently, it was extremely difficult to gather and analyse relevant information from conference data
It seems as if the conversation around the nature of healthcare’s AI future is one that’s been conducted without the voices of patients themselves
Patient support programmes (PSPs) provide one of the biggest opportunities for pharma to put a patient-centric philosophy into practice
It all starts with listening to patients
Across all industries, people are changing the ways they engage with products, services, and brands. View more...
Wednesday, 28 September 2016 - 11:00 am
George Underwood
FREE - Listen again now - | VIEW NOW
